The following stories appear in full on today's Vidyya Medical News Service Web site.
Two articles in today's issue contain information on cardiology devices that have been recently approved by the FDA. The first item, the Phylax AV Implantable Cardioverter Defibrillator (ICD) System with Programmer Software, is an implantable electronic device built inside a metal (titanium) shell that is placed under the skin in the shoulder area. The Phylax AV is used for patients who are at high risk of sudden death due to arrhythmia.
For more information: Phylax AV Implantable Cardioverter Defibrillator System With Programmer Software
The recently approved, Navi-Star ® catheter is a steerable thin flexible catheter (tube) containing multiple electrodes. This catheter can provide information about the location of the electrophysiological conduction responsible for heart muscle contraction.
For more information: New Device Information For Consumers: Navi-Star ® Diagnostic/Ablation Deflectable Tip Catheter
The US National Toxicology Program published its 500th two-year safety test of chemicals in rodents a landmark in a series that has influenced what is allowed in drugs, water, foods, and air, for these reports have often formed the foundation for regulatory action by the Food and Drug Administration, Environmental Protection Agency, Occupational Safety and Health Administration, and Consumer Product Safety Commission.
For more information: Rats! The NTP Completes 500th Two-Year Rodent Study Which Is The Gold Standard of Animal Toxicology
Naphthalene, the chemical that gives mothballs that strong, familiar scent, showed clear evidence of causing cancer in male and female laboratory rats in a two-year study by the National Toxicology Program headquartered at the National Institute of Environmental Health Sciences in Research Triangle Park, N.C. The rats in the study were exposed by inhalation, just as most people are, in doses comparable to some human consumer and workplace exposures.
For more information: Naphthalene Found To Cause Cancer In Famous Rat Study
Today's issue of The Lancet reports the results of a clinical trial that showed administration of the nutritional supplement, glucosamine sulfate, slows disease progression in patients with knee osteoarthritis. The three-year, double-blind, placebo-controlled study (Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Reginster J-Y, et al) was performed using 212 patients suffering from knee osteoarthritis who were randomly selected to receive 1500 mg once-a-day of oral glucosamine sulfate or a placebo for a three-year period.
For more information: Lancet Study Confirms: Glucosamine Sulfate Reduces Progression of Osteoarthritis
Today's Vidyya articles are:
As always, we hope you enjoy the issue.